(Total Views: 280)
Posted On: 11/18/2020 12:28:02 PM
Post# of 36566
And may drain NGIO too .....
10k :
Generex owns 364,003,151 of the aggregate 400,300,000 outstanding NGIO shares, or approximately 90.93% of NGIO’s outstanding shares. Generex may, in the future, sell some of its shares of NGIO, but Generex does not currently anticipate that its ownership level of NGIO will fall below 51%.
Epivax compensation:
As compensation, Generex will pay the following to EpiVax:
•Fee for Work Plan Completion: $150,000
•Technology Access Fee: $150,000 •Yearly renewal Fee: $25,000
•A royalty of 20% of payments received for the commercial sale of any product formulation which incorporates NuGenerex Ii-Key technology and EpiVax IP.
10k :
Generex owns 364,003,151 of the aggregate 400,300,000 outstanding NGIO shares, or approximately 90.93% of NGIO’s outstanding shares. Generex may, in the future, sell some of its shares of NGIO, but Generex does not currently anticipate that its ownership level of NGIO will fall below 51%.
Epivax compensation:
As compensation, Generex will pay the following to EpiVax:
•Fee for Work Plan Completion: $150,000
•Technology Access Fee: $150,000 •Yearly renewal Fee: $25,000
•A royalty of 20% of payments received for the commercial sale of any product formulation which incorporates NuGenerex Ii-Key technology and EpiVax IP.
(0)
(0)
